Lysine Demethylase 5A Is Required for MYC-Driven Transcription in Multiple Myeloma
Hiroto Ohguchi(Kumamoto University), Jun Qi(Georgia Institute of Technology), Yong Kim(National Institutes of Health), Shingo Usuki(Kumamoto University), Takashi Minami(Kumamoto University), Tingjian Wang(Dana-Farber Cancer Institute), Javed Khan(Kent State University), Masao Matsuoka(Kyoto University), Yu‐Tzu Tai(Harvard University), Chengkui Pei(Dana-Farber Cancer Institute), Paul M.C. Park(Dana-Farber Cancer Institute), Takeshi Masuda(Kumamoto University), Udo Oppermann(Oxford BioMedica (United Kingdom)), Kenneth C. Anderson(Dana-Farber Cancer Institute), Mitsuyoshi Nakao(Kumamoto University), Sumio Ohtsuki(Kumamoto University), Mehmet Samur(Dana-Farber Cancer Institute), Nikhil C. Munshi(Dana-Farber Cancer Institute), Yawara Kawano(Kumamoto University Hospital), C. Johansson(University of Oxford), Adam D. Durbin(St. Jude Children's Research Hospital), Keiji Kurata(Dana-Farber Cancer Institute), Deyao Li(Peking University), Daisuke Ogiya(Tokai University), Shinjiro Hino(Kumamoto University), Berkley E. Gryder(University School), Teru Hideshima(Harvard University), Virangika K. Wimalasena(Dana-Farber Cancer Institute), Xiaofeng Zhang(Harvard University), Shannon Lauberth(Northwestern University)
Cited by 41
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks
|Nature Medicine|2001|2.7k
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k